@article{ajmcr20219810,
author={{Azam, Silfat and Khalil, Abdalla and Taha, Ahmad},
title={Guillain-Barr¨¦ Syndrome in a 67-year-old Male Post COVID-19 Vaccination (Astra Zeneca)},
journal={American Journal of Medical Case Reports},
volume={9},
number={8},
pages={424--427},
year={2021},
url={http://pubs.sciepub.com/ajmcr/9/8/10},
issn={2374-216X},
abstract={Since the COVID-19 pandemic has started in December 2019, millions of people have been infected all over the world and few vaccines have been invented recently. Extremely rare, Guillain-Barre Syndrome (GBS) was reported as a neurological complication after H1N1 flu vaccination. Currently, Pfizer and AstraZeneca vaccines are available to prevent infection with COVID-19. The first case of post-COVID-19 vaccine GBS has been detected in a secondary care hospital after vaccination with AstraZeneca. A 67-year-old man presented with an acute progressive ascending flaccid symmetrical motor neuropathy, and bilateral facial weakness which developed two weeks after receiving the first dose of AstraZeneca COVID-19 vaccine. His cerebrospinal fluid findings, nerve conduction result, and MRI brain result were all in favour of GBS diagnosis. The patient¡¯s workup for all known infections associated with immune-mediated GBS was negative.},
doi={10.12691/ajmcr-9-8-10}
publisher={Science and Education Publishing}
}